No Data
No Data
Baihua Pharmaceutical (600721.SH) announced 2023 annual results with net profit of 129.723 million yuan, turning a year-on-year loss into profit
According to the Zhitong Finance App, Baihua Pharmaceutical (600721.SH) disclosed its 2023 annual report. The company achieved operating revenue of 369 million yuan during the reporting period, an increase of 5.54% over the previous year. Net profit attributable to shareholders of listed companies was 129.723 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.729 million yuan, turning losses into profits over the previous year. Basic earnings per share were 0.0342 yuan/share.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
Baihua Pharmaceutical (600721.SH): Does not involve AI technology
Gelonghui, March 26 | Baihua Pharmaceutical (600721.SH) said on the interactive platform that the company mainly provides customers with one-stop outsourcing and technological achievement transformation services for the whole process from drug discovery, pharmaceutical chemical component development, clinical trials and registration, without involving AI technology.
The A-share CRO sector declined at the beginning of the session, and Hongbo Pharmaceutical fell more than 8%
Glonghui, March 15 | Hongbo Pharmaceutical fell more than 8%, followed by Baihua Pharmaceutical, Norsgate, Pharmaceutical Kangde, and Jinkai Biotech.
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd's (SHSE:600721) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥405m Last Week
Key Insights The considerable ownership by individual investors in Xinjiang Bai Hua Cun Pharma TechLtd indicates that they collectively have a greater say in management and business strategy 41% of
A-share diet drug concept stocks fluctuated, and Changshan Pharmaceutical rose more than 7%
Gelonghui, Feb. 22 | Changshan Pharmaceutical rose more than 7%, followed by Baihua Pharmaceutical, Hanyu Pharmaceutical, Watson Pharmaceuticals, Jinkai Biotech, and Boji Pharmaceuticals.
No Data